Vutiglabridin (HSG4112) is a synthetic structural analog of glabridin and insulin sensitizer, novel anti-obesity agent.
HSG4112 dose-dependently reduces body weight and normalizes obesity-related parameters in HFD-induced obese mice orally administered with 10, 30, or 100 mg/kg dose for 6 weeks.
HSG4112 enhances energy expenditure in HFD-induced obese mice.
HSG4112 regulates metabolic gene expression toward increased energy expenditure in liver and muscles.
HSG4112 ameliorates fatty liver in HFD-induced obese mice orally administered with 100 mg/kg dose for 6 weeks
